Seattle Genetics under Clay Siegall Invents New Cancer Therapy

Seattle Genetics is a firm that was found in the year 1998 by Dr. Clay Siegall together with another co-founder. He was elected the company’s CEO and has been serving also as the chairman of the board and the president of the firm as well. The firm has developed a strong reputation for cancer drugs such as the ADCETRI, one of the drugs has received approval from the United States Food and Drug Administration since 2011.

Dr. Siegall is an active contributor to the success of the company’s financial growth. He has been guiding the company in acquiring funds from private and governmental companies and has managed to secure an amount more than $675 million. His career initially started at the Bristol-Myers Squibb Pharmaceutical Research Institute and earlier working with the National Cancer Institute, National Institute of Health. He forms part of the board of the Alder Biopharmaceutical company. His achievements in career include fifteen patents and have also published over seventy publications. He is also holding a Ph.D. IN Genetics and a Bachelors Degree in Zoology.

From the first instance of the Bothell’s Cascade Business Park won’t give the picture of edgy science. However, within the lobby, you find the triangular sculpture that is designed in the form of the human antibody. This is simply the symbol of the content making up the fiber of the company’s task since the year of its founding. The firm has majored into the study of the human antibody, manipulating them and incorporating them into the drug design for treatment. The cancer therapy designed with an antibody that attacks the cancer cell from the interiors, delivering a toxic payload to destroy the cell.

This therapy strategy has projected the Seattle Genetics into the position of the mighty. Seattle Genetics controls a market value of $10 billion and has a total number of 900 employees. It is in the rank as the top in the biotech field in the city of Washington. The company’s ambition is to rise from just a biotech company into a big pharma and to reach its target, it has invested in diverse research and marketing and plans to increase its workforce by bringing in 200 more employees. The company’s new drug discovery, the ADCETRIS, is a therapy that cures the cancer of the lymph known as Hodgkin lymphoma that poses a risk of also spread to other parts of the body. Research on the same drug continues and will be released to the market once approved positive.

Leave a Reply

Your email address will not be published. Required fields are marked *